Brussels, Belgium and Louisville, Kentucky, USA – May 21, 2012 – Peptisyntha and Peptides International announced today that they have entered into a global partnership for the production of research grade peptide APIs (active pharmaceutical ingredients)
Key to the partnership is saving time and costs to customers by providing a seamless progression and transfer of technical information from peptide candidate screening through preclinical and clinical development.
Peptides International, under the leadership of Dr. Michael Pennington, has custom peptide synthesis expertise across a wide range of technologies ranging from multi-disulfide peptides to multi-step organic synthesis. The company also offers an extensive portfolio of building blocks and other peptide synthesis tools and its activities have recently been certified to ISO 9001:2008 standards.
In complement to an impressive industry track record brought to the company by Dr. Mimoun Ayoub, Peptisyntha has developed and demonstrated over the years a unique set of expertise in the design of cost effective peptide manufacturing processes and in the cGMP production of clinical and commercial peptides APIs. Its facilities have had numerous successful FDA and EMEA inspections and offer a full range of solid phase, liquid phase, and hybrid synthesis capabilities.
Dr. Johan Devenyns, Managing Director of Peptisyntha stated: “Providing project continuity at all scales will save our customers time and resources while benefitting from our manufacturing expertise and excellent services.”
Dr. Bryce Johnson, Chief Executive Officer of Peptides International added: “This partnership represents the combination of over fifty years of peptide experience by two companies who share the same commitment to the highest standards of quality and operational excellence.”
Peptides International Inc. (PEPNET.COM)
Peptisyntha is a leading cGMP manufacturer of therapeutic peptides (peptide APIs) and peptidomimetics serving customers from the pharmaceutical, biotech, diagnostic and cosmetic industries. With 25 years of experience in peptide manufacturing Peptisyntha provides a seamless portfolio of expertise from lead optimization to commercial cGMP manufacturing. With two GMP manufacturing facilities in USA and Belgium, Peptisyntha masters all manufacturing technologies (SPPS, LPPS and hybrid approaches) at all scales Peptisyntha is a wholly owned company of Solvay, an international chemical group active in chemistries contributing to improving quality of life. Please visit http://www.peptisyntha.com.